



ditu u pacientů s DM2 a tyto přípravky jsou v rámci doporučení tlačeny na přední místa v léčbě, nelze zapomínat i na lety prověřený pioglitazon, který má k dispozici rovněž data o příznivém ovlivnění kardiovaskulárních komplikací, ale také disponuje daty o příznivém ovlivnění jednotlivých složek metabolického syndromu, což tento efekt pochopitelně umocňuje.

LITERATURA

1. Low Wang CC, Hess CN, Hiatt WR, et al. Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus – mechanisms, management, and clinical considerations. *Circulation* 2016;133:2459-2502.
2. DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links: the Claude Bernard Lecture 2009. *Diabetologia*. 2010;53:1270-1287.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet*. 1998;352:837-853.
4. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ*. 2000;321:405-412.
5. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. *Diabetes*. 1996 Dec;45(12):1661-9. doi: 10.2337/diab.45. 12. 1661.
6. DeFronzo RA, Inzucchi S, Abdul-Ghani M, Nissen SE. Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes. *Diab Vasc Dis Res*. 2019;16:133-143.
7. Goldberg RB, Kendall DM, Deeg MA, et al.; GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. *Diabetes Care*. 2005;28:1547-1554.
8. Alam F, Islam MA, Mohamed M, et al. Efficacy and Safety of Pioglitazone Monotherapy in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. *Sci Rep*. 2019;9:5389.
9. DeFronzo RA, Tripathy D, Schwenke DC, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. *New Engl J Med*. 2011;364:1104-1115.
10. Deeg MA, Buse JB, Goldberg RB, et al.; GLAI Study Investigators. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. *Diabetes Care*. 2007;30:2458-2464.
11. [https://www.ema.europa.eu/en/documents/product-information/pioglitazone-actavis-](https://www.ema.europa.eu/en/documents/product-information/pioglitazone-actavis-epar-product-information_cs.pdf)

je. Nelze rovněž podceňovat jeho vliv na zlepšení inzulinové rezistence, ochranný vliv na endotel a B-buňky. Navíc je pioglitazon nyní dostupný i ve formě generických preparátů, což dále léčbu zlevňuje. V neposlední řadě byla zmírněna i preskripční omezení, která nyní neobsahují hranici HbA1c, doporučenou k zahájení léčby.

-epar-product-information_cs.pdf

12. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. *JAMA*. 2006;296:2572-2581.
13. Koshiyama H, Shimono D, Kuwamura N, et al. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. *J Clin Endocrinol Metab*. 2001;86:3452-3456.
14. Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. *JAMA*. 2008;299:1561-1573.
15. Nishio K, Sakurai M, Kusuyama T, et al. A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes. *Diabetes Care*. 2006;29:101-106.
16. Patel D, Walitt B, Lindsay J, Wilensky RL. Role of pioglitazone in the prevention of restenosis and need for revascularization after bare-metal stent implantation: a meta-analysis. *J Am Coll Cardiol Interv*. 2011;4:353-360.
17. Althouse AD, Abbott JD, Sutton-Tyrrell K, et al. Favorable effects of insulin sensitizers pertinent to peripheral arterial disease in type 2 diabetes: results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. *Diabetes Care*. 2013;36:3269-3275.
18. Dormandy JA, Betteridge DJ, Schernthaner G, et al. PROactive investigators. Impact of peripheral arterial disease in patients with diabetes – results from PROactive (PROactive 11). *Atherosclerosis*. 2009;202:272-281.
19. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitazone clinical trial in macrovascular events): a randomized controlled trial. *Lancet*. 2005;366:1279-1289.
20. Erdmann E, Dormandy JA, Charbonnel B, et al. The effect of pioglitazone on recurrent